CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
November 9th 2024
MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from treatment with targeted therapies.
Testing Only the 'Tip of the Iceberg' for Common Hereditary Condition in MSI-H Tumors
June 14th 2018Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Frontline Keytruda Effective in NSCLC Subgroup, But More Work Is Needed
June 13th 2018In the Keynote-042 trial, researchers found a four- to eight-month overall survival benefit among patients with non-small cell lung cancer (NSCLC), which was correlated with higher levels of PD-L1 expression, however, further study is warranted.
Broader Genetic Testing Can Save Costs, Determine Treatment Plans in Lung Cancer
June 1st 2018Using next-generation sequencing (NGS) to test patients with non-small cell lung cancer (NSCLC) for all known genetic mutations associated with the disease appeared to be faster and more cost-effective than testing for one gene at a time – not to mention the results could have treatment implications.
Tecentriq Granted Priority Review to Treat Lung Cancer
May 7th 2018The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) to be used in combination with Avastin (bevacizumab), carboplatin and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).
FDA Grants Priority Review for Immunotherapy-Based Lung Cancer Combination
April 30th 2018The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), according to Merck (MSD), the manufacturer of the PD-1 inhibitor.
FDA Grants Opdivo Priority Review for Small Cell Lung Cancer
April 19th 2018The Food and Drug Administration (FDA) granted priority review to a supplemental biologics license application for Opdivo (nivolumab) for the treatment of patients with small cell lung cancer with disease progression following two or more lines of therapy.
Frontline Opdivo-Yervoy Combo Shows Promise in Advanced Non-Small Cell Lung Cancer
April 17th 2018Most recently, the dynamic duo of Yervoy (ipilimumab) plus Opdivo (nivolumab) – both checkpoint inhibitors – extended average progression-free survival (PFS) rates more than three times than standard-of-care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB).
New Guidelines Aim to Improve Quality of Life For Patients With Advanced Lung Cancer
April 12th 2018Some patients with incurable non-small cell lung cancer (NSCLC) should receive chemotherapy concurrent with palliative thoracic radiation therapy, according to an updated guideline released by the American Society for Radiation Oncology (ASTRO).
FDA Grants Lorlatinib a Priority Review for Lung Cancer Treatment
February 13th 2018Lorlatinib was granted a priority review to a new drug application (NDA) for patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinases inhibitors (TKIs).
Bipartisan Act Puts Focus on Women With Lung Cancer
February 6th 2018Lung cancer is the leading cause of cancer-related death for women in the United States, but often does not get as much attention as other malignancies. In an effort to change that, and to one day decrease the number of women who are dying from the disease, the bipartisan Women and Lung Cancer Research and Preventative Services Act was reintroduced into Congress.
Adding Tecentriq to Chemo Regimen Improves Lung Cancer Outcomes
January 31st 2018Not all patients with non-small cell lung cancer (NSCLC) respond to immunotherapy, so researchers are exploring the use of combination regimens, including immune checkpoint inhibitors and chemotherapy, to improve outcomes in these patients.
Gilotrif's Approval Expanded to Some Patients With Metastatic NSCLC
January 15th 2018The Food and Drug Administration (FDA) expanded the approved use for Gilotrif (afatinib). The drug can now be used to treat patients with metastatic non-small cell lung cancer (NSCLC) who have uncommon EGFR alterations in L861Q, G719X and/or S768I.